New drug combo for advanced mouth and throat cancer
Part of Cancer clinical trials.
This trial tests whether two new drugs (becotatug vedotin and pucotenlimab) work better than standard surgery and radiation for locally advanced oral or oropharyngeal squamous cell carcinoma. The drugs are given before surgery to shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with stage III or IVa oral or oropharyngeal squamous cell carcinoma (cancer in mouth, tongue, throat, or tonsils)
- Cancer must have specific protein markers (PD-L1 and EGFR) shown on biopsy testing
- No evidence that cancer has spread to distant parts of body
- Age 18–75 with good overall health (ECOG 0–1)
- No prior cancer treatment for this tumor
- Normal or near-normal blood counts, kidney, liver, and thyroid function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new cancer-fighting drugs together to treat advanced squamous cell carcinoma (a common type of head and neck cancer) in patients who cannot tolerate or refuse platinum-based chemotherapy. The goal is to see if this combination can shrink or control the cancer.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
This trial is for people with advanced head and neck cancer that has not been treated yet. It tests a combination of an immunotherapy drug (Pucotenlimab) and chemotherapy given before surgery to see if it can shrink tumors and improve outcomes.
This study tests two medications given before surgery to shrink mouth cancer and improve outcomes. It is for people with a certain type of mouth cancer that has not been treated yet and can be removed with surgery.
This trial tests a combination of three drugs (MRG003, pucotenlimab, and possibly cisplatin) given before surgery for people with a specific type of head and neck cancer that is EGFR-positive and has not been treated yet. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.